Innovations in Malaria Vaccine Development (IMV)
Closed Special Notice Posted
- Solicitation number
- GH-BAA-2018-Addendum03
- Agency
- Washington Office US Agency for International Development
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
Notice details come from SAM.gov. Updated .
About this opportunity
The USAID published a Special Notice seeking novel approaches to malaria vaccine development through a collaborative design process. The goal is to demonstrate proof of concept for a vaccine that reduces morbidity and mortality caused by Plasmodium falciparum malaria with at least 75% efficacy and evidence of affordability, targeting pre-erythrocytic and erythrocytic stages.
USAID solicits Expressions of Interest for approaches encompassing preclinical development through proof of principle clinical studies to advance a deployable, effective malaria vaccine. The deadline to submit Expressions of Interest is June 21, 2019. Eligible applicants include private sector, academic, and nonprofit organizations. Selected applicants will be invited to participate in a collaborative design workshop in August or September 2019 to develop concept papers addressing next-generation malaria vaccines, which USAID may fund up to $35.5 million over five years through contracts or other agreements.
Notice text
USAID is seeking to enhance our malaria vaccine investments through a collaborative design process. The goal of USAID’s Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle. The purpose of this Addendum is to solicit Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine..
Attachments
| File | Type | Posted |
|---|---|---|
| GH-BAA-2018-Addendum03.Amendment1.pdf | ||
| GH-BAA-2018-Addendum03.Amendment1.pdf | ||
| GH-BAA-2018-Addendum03.Amendment1.pdf | ||
| GH-BAA-2018-Addendum03.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity